PUBLISHER: GlobalData | PRODUCT CODE: 1535211
PUBLISHER: GlobalData | PRODUCT CODE: 1535211
Influenza Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative and qualitative market trends within In Vitro Diagnostics therapeutic area.
Influenza, also called flu or grippe, is an acute viral infection of the upper or lower respiratory tract that is marked by fever, chills, and a generalized feeling of weakness and pain in the muscles, together with varying degrees of soreness in the head and abdomen. Influenza viruses are categorized as types A, B, C, and D. These major types generally produce similar symptoms but are completely unrelated antigenically, so that infection with one type confers no immunity against the others. Influenza type A and B viruses cause the vast majority of influenza diseases in humans, and infection is preventable by vaccination.
Influenza tests are diagnostic tests used to detect the presence of the influenza virus in a patient's respiratory system. The choice of influenza test depends on a variety of factors, including the severity of the patient's illness, the timing of the test, and the availability of testing facilities.
Each of the covered 39 countries color-coded and fully-sourced market models are equipped with epidemiology based indications. The interactive excel deliverable covers value, volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.
Key Inclusions of the market model are:
Currently marketed Influenza Test and evolving competitive landscape:
2015- 2033.
Global, Regional and Country level market specific insights:
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Companies covered: Abbott Laboratories, Cepheid Inc, Quidel Corp, Roche Diagnostics International Ltd, DiaSorin Molecular LLC + Luminex Corp, Becton Dickinson and Co, Qiagen NV, Thermo Fisher Scientific Inc, bioMerieux SA, Sekisui Diagnostics LLC, and Others.
Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.
This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -
The model will enable you to -